We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unveiling Hologic (HOLX) Q4 Outlook: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Hologic (HOLX - Free Report) will report quarterly earnings of $0.85 per share in its upcoming release, pointing to a year-over-year increase of 3.7%. It is anticipated that revenues will amount to $941.4 million, exhibiting a decline of 1.3% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 2.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Hologic metrics that are commonly monitored and projected by Wall Street analysts.
Analysts' assessment points toward 'Revenue- GYN Surgical' reaching $141.55 million. The estimate points to a change of +6.2% from the year-ago quarter.
Analysts expect 'Revenues- Diagnostics- Molecular Diagnostics' to come in at $313.31 million. The estimate indicates a change of -21.7% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Diagnostics- Blood Screening' will reach $8.04 million. The estimate points to a change of +1.8% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Breast Health- Breast Imaging' of $269.14 million. The estimate points to a change of +27% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Total Diagnostics' will reach $434.70 million. The estimate indicates a change of -16.6% from the prior-year quarter.
Analysts predict that the 'Revenue- Skeletal Health' will reach $25.24 million. The estimate points to a change of +5.2% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Diagnostics- Cytology & Perinatal' will likely reach $113.34 million. The estimate indicates a change of +0.5% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Total Breast Health' at $340.58 million. The estimate indicates a change of +23.8% from the prior-year quarter.
Analysts forecast 'Revenues- Breast Health- Interventional Breast Solutions' to reach $71.44 million. The estimate indicates a change of +13.2% from the prior-year quarter.
According to the collective judgment of analysts, 'Service and other revenue' should come in at $172.03 million. The estimate indicates a change of +0.8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Product Sales' should arrive at $767.27 million. The estimate indicates a year-over-year change of -2%.
Shares of Hologic have experienced a change of -1.7% in the past month compared to the +3.1% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), HOLX is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unveiling Hologic (HOLX) Q4 Outlook: Wall Street Estimates for Key Metrics
Wall Street analysts forecast that Hologic (HOLX - Free Report) will report quarterly earnings of $0.85 per share in its upcoming release, pointing to a year-over-year increase of 3.7%. It is anticipated that revenues will amount to $941.4 million, exhibiting a decline of 1.3% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 2.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Hologic metrics that are commonly monitored and projected by Wall Street analysts.
Analysts' assessment points toward 'Revenue- GYN Surgical' reaching $141.55 million. The estimate points to a change of +6.2% from the year-ago quarter.
Analysts expect 'Revenues- Diagnostics- Molecular Diagnostics' to come in at $313.31 million. The estimate indicates a change of -21.7% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Diagnostics- Blood Screening' will reach $8.04 million. The estimate points to a change of +1.8% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Breast Health- Breast Imaging' of $269.14 million. The estimate points to a change of +27% from the year-ago quarter.
It is projected by analysts that the 'Revenue- Total Diagnostics' will reach $434.70 million. The estimate indicates a change of -16.6% from the prior-year quarter.
Analysts predict that the 'Revenue- Skeletal Health' will reach $25.24 million. The estimate points to a change of +5.2% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Diagnostics- Cytology & Perinatal' will likely reach $113.34 million. The estimate indicates a change of +0.5% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Total Breast Health' at $340.58 million. The estimate indicates a change of +23.8% from the prior-year quarter.
Analysts forecast 'Revenues- Breast Health- Interventional Breast Solutions' to reach $71.44 million. The estimate indicates a change of +13.2% from the prior-year quarter.
According to the collective judgment of analysts, 'Service and other revenue' should come in at $172.03 million. The estimate indicates a change of +0.8% from the prior-year quarter.
Based on the collective assessment of analysts, 'Product Sales' should arrive at $767.27 million. The estimate indicates a year-over-year change of -2%.
View all Key Company Metrics for Hologic here>>>
Shares of Hologic have experienced a change of -1.7% in the past month compared to the +3.1% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), HOLX is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>